Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05961527

Group MDMA-therapy for Veterans With PTSD (Group-MVP)

An Open-Label Feasibility and Safety Study of MDMA-Assisted Group Therapy for the Treatment of Posttraumatic Stress Disorder in Veterans

Sponsor: Portland VA Research Foundation, Inc

Conditions PTSD

Interventions Group Therapy MDMA

Updated 6 times since 2023 Last updated: Jun 9, 2025 Started: Oct 1, 2023 Primary completion: Mar 14, 2025 Completion: Mar 14, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05961527, this PHASE1/PHASE2 trial focuses on PTSD and remains completed. Sponsored by Portland VA Research Foundation, Inc, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Jul 2025 — Present [monthly]

Completed PHASE1/PHASE2

Status: Active Not Recruiting → Completed
Sep 2024 — Jul 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Aug 2023 — Nov 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Portland VA Research Foundation, Inc
Steven & Alexandra Cohen Foundation

Data source: Portland VA Research Foundation, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vancouver, United States